Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOTPJD)

Drug Name
Rockout Drug Info
Synonyms
3-(Pyridin-4-yl)-1H-indole; 3-(4-Pyridyl)indole; rockout; 3-(pyridin-4-yl)-1H-indole; 7272-84-6; 3-Pyridin-4-yl-1H-indole; 3-(4-Pyridyl)-1H-indole; Rho Kinase Inhibitor III, Rockout; 3-(4-Pyridinyl)-1H-indole; CHEMBL380071; 1H-indole, 3-(4-pyridinyl)-; 3-(4-Pyridyl); Rho kinase inhibitor III; ChemDiv2_000332; AC1LD92F; Oprea1_292323; Oprea1_060403; CBDivE_015772; MLS000029246; SCHEMBL238277; GTPL6032; cid_644354; ZINC80555; CHEBI:93984; DTXSID90349379; 3-(PYRIDIN-4-YL)INDOLE; MolPort-001-899-519; HMS1369P02; HMS3229K13; HMS2280K08; STL331403; IN1125; BDBM50182878; rockout
Cross-matching ID
PubChem CID
644354
ChEBI ID
CHEMBL380071
CAS Number
CAS 7272-84-6
TTD Drug ID
D0L0MJ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.17 0.00e+0 34/36 (94.44%) PCNA;MCM4;MCM6;...
Ribosome 2.09 0.00e+0 113/158 (71.52%) RPS4Y1;MRPL15;MRPL13;...
Valine, leucine and isoleucine degradation 2.00 0.00e+0 42/48 (87.5%) DLD;ABAT;ACAA2;...
Ribosome biogenesis in eukaryotes 1.94 1.56e-3 52/108 (48.15%) POP5;RPP38;REXO2;...
Oxidative phosphorylation 1.94 1.24e-3 93/133 (69.92%) NDUFA5;CYC1;SDHD;...
Cell cycle 1.92 2.07e-3 110/124 (88.71%) PCNA;CDC20;MCM4;...
Pyrimidine metabolism 1.88 2.67e-3 40/56 (71.43%) TYMS;RRM2;ENPP1;...
One carbon pool by folate 1.85 4.67e-3 15/20 (75%) TYMS;DHFR;MTHFD1;...
Pantothenate and CoA biosynthesis 1.83 5.53e-3 14/21 (66.67%) AASDHPPT;ENPP1;DPYS;...
Fatty acid degradation 1.74 1.56e-2 40/43 (93.02%) ACAA2;ACAT1;ACAT2;...
Mismatch repair 1.64 4.64e-2 22/23 (95.65%) PCNA;RPA3;RFC4;...
Thermogenesis 1.64 4.36e-2 173/232 (74.57%) NDUFAF4;NDUFA5;CYC1;...
Pyruvate metabolism 1.64 4.02e-2 41/47 (87.23%) DLD;DLAT;PCK1;...
Citrate cycle (TCA cycle) 1.62 4.13e-2 30/30 (100%) DLD;IDH3A;DLAT;...
Alanine, aspartate and glutamate metabolism 1.62 3.86e-2 27/37 (72.97%) ASS1;ABAT;CAD;...
Base excision repair 1.58 4.74e-2 29/33 (87.88%) PCNA;POLE2;FEN1;...
Pentose phosphate pathway -1.81 5.33e-3 25/30 (83.33%) ALDOA;TKT;ALDOC;...
Galactose metabolism -1.81 5.48e-3 26/31 (83.87%) HK3;AKR1B1;GLB1;...
Phagosome -1.82 4.89e-3 118/152 (77.63%) ITGB1;ATP6AP1;ITGA5;...
Cytokine-cytokine receptor interaction -1.83 4.64e-3 246/295 (83.39%) TNFSF12;IL5RA;CD40;...
Lysosome -1.83 4.38e-3 115/128 (89.84%) CTSH;MAN2B1;GALNS;...
Graft-versus-host disease -1.84 4.52e-3 32/42 (76.19%) HLA-G;IL6;KIR2DL1;...
Toxoplasmosis -1.84 4.24e-3 103/112 (91.96%) AKT1;HLA-DRA;JAK1;...
Allograft rejection -1.84 4.38e-3 32/38 (84.21%) HLA-G;IL5;HLA-F;...
Yersinia infection -1.86 4.54e-3 120/137 (87.59%) ARPC1A;MAP2K6;IRF3;...
Salmonella infection -1.87 4.70e-3 198/249 (79.52%) ARPC1A;CYTH1;MAP2K6;...
NF-kappa B signaling pathway -1.88 4.87e-3 90/104 (86.54%) CSNK2B;CD40;PLAU;...
Th1 and Th2 cell differentiation -1.90 5.06e-3 80/92 (86.96%) HLA-DRA;JAK1;GATA3;...
Rheumatoid arthritis -1.90 5.26e-3 78/93 (83.87%) ATP6V1F;VEGFA;TGFB1;...
Shigellosis -1.94 5.42e-3 180/246 (73.17%) ARPC1A;CYTH1;ATG12;...
Influenza A -1.96 3.29e-3 156/172 (90.7%) CDK4;IRF3;MAP2K1;...
Osteoclast differentiation -1.98 3.51e-3 117/127 (92.13%) MAP2K1;TGFB1;CSF1R;...
Chemokine signaling pathway -1.98 3.76e-3 163/192 (84.9%) MAP2K1;STAT2;GNAI3;...
Pathogenic Escherichia coli infection -1.98 4.05e-3 152/197 (77.16%) CLDN8;ARPC1A;CYTH1;...
C-type lectin receptor signaling pathway -2.00 4.38e-3 93/104 (89.42%) AKT1;PIK3CD;IL23A;...
TNF signaling pathway -2.00 3.59e-3 103/112 (91.96%) LTA;MAP2K6;MAP2K1;...
Pertussis -2.02 2.63e-3 64/76 (84.21%) IRAK4;IL23A;ITGB1;...
Epithelial cell signaling in Helicobacter pylori infect... -2.02 2.92e-3 62/70 (88.57%) F11R;ATP6AP1;ATP6V0E1;...
IL-17 signaling pathway -2.02 3.29e-3 84/94 (89.36%) CCL17;JUND;RELA;...
Natural killer cell mediated cytotoxicity -2.03 3.76e-3 99/131 (75.57%) MAP2K1;MAP2K2;CD48;...
Neutrophil extracellular trap formation -2.03 4.38e-3 101/189 (53.44%) MAP2K1;MAP2K2;ITGA2B;...
NOD-like receptor signaling pathway -2.05 5.26e-3 145/181 (80.11%) ATG12;IRF3;CASR;...
Antigen processing and presentation -2.10 3.29e-3 60/78 (76.92%) HLA-F;CD74;HSP90AA1;...
Lipid and atherosclerosis -2.11 4.38e-3 190/215 (88.37%) PRKCA;POU2F1;PPARG;...
Fructose and mannose metabolism -2.13 0.00e+0 30/33 (90.91%) HK1;PFKFB4;PMM1;...
Viral protein interaction with cytokine and cytokine re... -2.26 0.00e+0 84/100 (84%) CXCL3;IL18RAP;CXCR4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 10uM 6H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.03uM - 10uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H